Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

TissueGene-C for Knee Osteoarthritis

TissueGene-C is an allogeneic cell and gene therapy delivered via intra-articular injection in development for the treatment of knee osteoarthritis.

Radiolabeled Omburtamab for Metastatic Neuroblastoma

Omburtamab is a radiolabeled monoclonal antibody targeting tumor antigen B7-H3 in development for intraventricular radioimmunotherapy for treatment of neuroblastoma central nervous system/leptomeningeal metastases.

CureSight for Amblyopia in Children

CureSight is a software-based prescription digital therapeutic for treatment of amblyopia that utilizes eye tracking technology to improve visual acuity and stereo acuity by training the visual system to use both eyes simultaneously.